ALZ-801
Cat. No.: DC11301
Featured
Chemical Structure
1034190-08-3
We are official vendor of:
More than 5000 active chemicals with high quality for research!
Field of application
ALZ-801 is a potent and orally available small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor, valine-conjugated prodrug of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound. ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer’s disease.
| Cas No.: |
1034190-08-3 |
| Chemical Name: |
(S)-3-(2-aMino-3-MethylbutanaMido)propane-1-sulfonic acid |
| Synonyms: |
ALZ-801,ALZ801,ALZ 801 |
| SMILES: |
C(S(O)(=O)=O)CCNC(=O)[C@H](N)C(C)C |
| Formula: |
C8H18N2O4S |
| M.Wt: |
238.302 |
| Purity: |
>98% |
| Sotrage: |
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Publication: |
1. Kocis P, et al. CNS Drugs. 2017 Jun;31(6):495-509.
2. Hey JA, et al. Clin Pharmacokinet. 2018 Mar;57(3):315-333. |
| Description: |
ALZ-801 is an orally available, small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor, valine-conjugated prodrug of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound[1]. ALZ-801 is an advanced and markedly improved clinical candidate for the treatment of Alzheimer’s disease[2]. |
| Target: |
β-amyloid[1] |
| References: |
[1]. John A. Hey, et al. Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain. CNS Drugs. 2018; 32(9): 849–861.
[2]. Hey JA, et al. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease. Clin Pharmacokinet. 2018 Mar;57(3):315-333. |
MSDS
COA
| LOT NO. |
DOWNLOAD |
|
|
| 2018-0101 |
|
| 2018-0101 |
|
Get Quote
